Rebecca Greenberg, Founder and CEORebecca Greenberg, founder and CEO of DeepThink Analytics, shifts the conversation by asking pharma companies, ‘What’s the smallest, most meaningful step you can take right now?’
This is her first step to guide clients through digital transformation and AI implementation projects with a practical and feasible approach. Her strategy is use case driven, focusing on real-world scenarios, where AI or digital tools can offer immediate, tangible value, helping clients make progress without being overwhelmed by large-scale, abstract solutions.
According to Greenberg, AI doesn’t need to transform a business’ entire operation overnight. Sometimes, the best place to start is with the everyday tasks that slow the teams down. Start small, and the momentum to drive change takes care of itself.
“My clients are the experts in their world. My role is to help them rethink the systems they already know and navigate change without chaos. We don’t sell solutions—we co-create them,” says Greenberg.
That’s why Greenberg’s method stands out. As a technology-agnostic, she understands many companies are already locked into AWS, Databricks, or legacy systems they can’t easily replace, while others simply lack the budget for sweeping, all-at-once AI rollouts.Her approach begins with a pragmatic assessment of the organization’s current assets, prioritizing efficiency over costly, complex solutions. This can involve leveraging in-house tools—such as using Copilot to draft L&D scripts—or initiating low-risk, high-value pilot projects.
-
My clients are the experts in their world. My role is to help them rethink the systems they already know and navigate change without chaos. We don’t sell solutions—we co-create them
In some cases, it is as straightforward as organizing messy spreadsheets, where one person puts ‘Cape Canaveral, Florida’ in a single cell and someone else splits it across three columns. This step helps clients recognize how much of their digital transformation journey still lies ahead while gaining a clearer understanding of what true digital transformation entails. Small wins like these build trust and momentum. Once people see what’s possible, they’re more open to exploring larger-scale solutions that add more value.
Greenberg achieves this by leading with the right questions — the kind that help clients surface the answers they had all along.
A compelling case in point is a client who wanted to build a dashboard to consolidate all their data, expecting it to be a simple three-month project at five hours a week. It quickly became clear they weren’t ready. Data was scattered across spreadsheets, work was duplicated, key information was missing, and manual processes, especially around budgets, were inconsistent and unreliable. At one point, the client asked, “Can’t we just plug in one of those AI tools to fix this?” That question exposed the real issue: their systems were too fragmented for AI to deliver value. Greenberg helped them confront that reality and led the critical cleanup—completed on time and laying the foundation for meaningful progress.
It’s what Greenberg does best. She has always been drawn to complexity, not by following the usual playbook, but by stepping into the mess, uncovering what’s broken, and making it work. By challenging outdated processes and digging into habits that no longer serve a purpose, she helps organizations cut waste, save resources, and empower teams to own the transformation.
When pharma companies are overwhelmed by AI hype, she brings clarity, helping pharma companies start small, think practically, and build real momentum. Greenberg’s approach proves that meaningful transformation starts with asking better questions and refusing to settle for “that’s how it’s always been done.”
Practical AI Advisory For Pharma Teams
Pharma AI programs often stall before a model is selected. The real blockage is scattered data and entrenched workarounds, compounded by uncertainty over where automation belongs. Large platform pitches make the decision harder when they assume broad replacement and long implementation cycles at budgets few teams can defend. A poor start wastes staff time and delays approvals. Distrust then follows later initiatives. Executive teams need advice that separates useful near-term work from infrastructure debt without turning every gap into a multiyear program.
Technology neutrality matters because most life sciences firms already own more software than they use well. A credible adviser should begin with installed platforms, contract limits, security requirements and staff habits. The question is not which new suite has the widest feature set. It is whether current tools can support a defined use case. Remaining data work and any new purchase should then be tied to a named constraint. Neutrality is proven by a willingness to recommend no purchase at all. Budget discipline belongs inside the technical judgment, not in a separate commercial exercise. Advice becomes expensive when it starts from a vendor architecture rather than the client’s actual environment.
Pilot design is another dividing line. Pharma teams do not need a theatrical demonstration detached from daily work. They need a bounded task whose output can be checked by the people who already own the process. Repetitive reporting, document preparation, meeting follow-up and internal knowledge retrieval may offer clearer starting points than scientific applications that demand deeper validation. A small deployment should reveal adoption barriers and data inconsistencies while giving staff enough exposure to judge usefulness. Its output should be measurable against the current method, yet modest enough to revise without sunk-cost pressure. Training should be built around the job itself rather than a generic lesson on AI. A pilot that exposes poor source data or duplicated work has still served its purpose if it prevents a premature build.
“Technology neutrality matters because most life sciences firms already own more software than they use well.”
Project control cannot be reduced to technical completion. Pharma programs routinely cross business and IT groups that use the same terms differently or carry old process rules no one can explain. Strong advisory work makes those assumptions visible and establishes shared language. It also keeps decisions close to end users while recording why each choice was made. An adviser should create feedback loops early enough to change course without turning every revision into a governance dispute. Decision records, plain-language process maps, named owners and documented exceptions should remain with the client. The lasting test is whether the organization understands the process well enough to own it after the engagement.
For pharma and biotech teams that need a measured start, DeepThink Analytics is the premier choice. Its technology-agnostic approach begins with existing systems and current work rather than a predetermined platform sale. Using bounded, low-risk pilots, it identifies practical AI use cases and expose data problems. Staff confidence develops through direct use rather than a glossy roadmap. Its project management model focuses on shared language, enduser feedback, process ownership and disciplined scope. This combination suits organizations facing budget limits or uneven digital readiness. DeepThink Analytics is best considered where the immediate need is informed progress, not wholesale system replacement.
...Read more
Pharma Technology-Agnostic Advisory Services Info
Q1
What Should Organizations Understand About Pharma Technology Agnostic Advisory Services?
Pharma Technology Agnostic Advisory Services help pharmaceutical organizations evaluate digital tools, data approaches and artificial intelligence initiatives without being tied to a specific technology provider. These services focus on understanding business challenges first, then identifying practical options that fit existing systems, resources and goals. For pharma teams managing complex data environments, legacy platforms and compliance requirements, this approach helps avoid unnecessary technology investments and focuses attention on solutions that address real workflow problems.
Q2
How Does DeepThink Analytics Support Pharma Technology Agnostic Advisory Services?
DeepThink Analytics provides Pharma Technology Agnostic Advisory Services by helping pharmaceutical organizations approach digital adoption through practical, use-case-driven planning. The company focuses on identifying smaller steps that can deliver measurable value rather than pushing large technology programs without clear outcomes. Its approach includes assessing existing systems, understanding organizational challenges and finding ways to use available tools more effectively. DeepThink Analytics works with organizations to rethink existing processes and build realistic pathways for digital and AI adoption.
Q3
Why Is A Technology-Neutral Approach Important For Pharma Digital Initiatives?
A technology-neutral approach allows pharmaceutical organizations to focus on business needs before selecting platforms or tools. Pharma Technology Agnostic Advisory Services help teams avoid adopting technology simply because it is new or widely promoted. Instead, these services examine current workflows, data readiness and operational gaps to determine where technology can create meaningful improvements. This approach is especially useful when organizations already operate across multiple systems and need practical guidance on improving efficiency without replacing everything at once.
Q4
How Can Pharma Companies Evaluate Digital Transformation Opportunities?
Evaluating digital transformation opportunities requires more than selecting advanced tools. Pharma Technology Agnostic Advisory Services help organizations review their current processes, identify bottlenecks and determine whether they have the necessary data foundation for successful implementation. DeepThink Analytics uses a practical assessment approach that looks at existing assets, available technologies and areas where small improvements can create momentum. The company highlights that issues such as fragmented spreadsheets, inconsistent processes and disconnected information can limit the value of advanced analytics or AI initiatives.
Q5
How Are Pharma Technology Agnostic Advisory Services Helping Organizations Approach AI Adoption?
Pharma Technology Agnostic Advisory Services provide a structured way for organizations to explore AI adoption without committing to complex programs before understanding their needs. Many pharmaceutical companies face challenges related to integration costs, compliance expectations and existing infrastructure limitations. Advisory support helps teams identify manageable use cases, test potential applications and build confidence through practical results. This approach allows organizations to develop AI strategies based on real operational requirements rather than technology trends alone.
Q6
What Role Does Data Readiness Play In Pharma Technology Agnostic Advisory Services?
Data readiness is a key consideration in Pharma Technology Agnostic Advisory Services because digital tools depend on reliable information and organized workflows. Before implementing advanced analytics or AI solutions, organizations need to understand how data is collected, stored and used across teams. DeepThink Analytics emphasizes starting with foundational improvements, such as organizing information and improving existing processes, before expanding into larger digital initiatives. This approach helps pharmaceutical organizations create stronger conditions for sustainable technology adoption.
